AbCellera Biologics Inc.: net finite-lived intangible assets
Net finite-lived intangible assets for AbCellera Biologics Inc. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All AbCellera Biologics Inc. financial histories
What this measure means
Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.
Exact concept: us-gaap:FiniteLivedIntangibleAssetsNet. Each value is a balance at the reporting date, not a flow earned over a year. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2021-12-31 to 2025-12-31. The SEC response was captured on 2026-09-19.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| At date | 2025-12-31 | 17,560,000 | USD | 2026-02-24 | 10-K · 0001703057-26-000012 |
| At date | 2024-12-31 | 18,660,000 | USD | 2025-02-27 | 10-K · 0001628280-25-008689 |
| At date | 2023-12-31 | 22,100,000 | USD | 2024-02-20 | 10-K · 0001703057-24-000019 |
| At date | 2022-12-31 | 29,158,000 | USD | 2023-02-21 | 10-K · 0001564590-23-002128 |
| At date | 2021-12-31 | 34,542,000 | USD | 2022-02-25 | 10-K · 0001564590-22-007077 |
Related financial histories
- AbCellera Biologics Inc.: total assets
- AbCellera Biologics Inc.: total liabilities
- AbCellera Biologics Inc.: stockholders equity
- AbCellera Biologics Inc.: cash and cash equivalents
- AbCellera Biologics Inc.: net income or loss
- AbCellera Biologics Inc.: operating cash flow
- AbCellera Biologics Inc.: capital expenditure payments
- AbCellera Biologics Inc.: contract revenue excluding tax
- AbCellera Biologics Inc.: financing cash flow
- AbCellera Biologics Inc.: investing cash flow
- AbCellera Biologics Inc.: retained earnings or deficit
- AbCellera Biologics Inc.: basic weighted-average shares
- AbCellera Biologics Inc.: diluted weighted-average shares
- AbCellera Biologics Inc.: basic earnings per share
- AbCellera Biologics Inc.: diluted earnings per share
- AbCellera Biologics Inc.: income tax expense or benefit
- AbCellera Biologics Inc.: net property, plant and equipment
- AbCellera Biologics Inc.: share-based compensation expense
- AbCellera Biologics Inc.: operating income or loss
- AbCellera Biologics Inc.: current assets
- AbCellera Biologics Inc.: current liabilities
- AbCellera Biologics Inc.: goodwill carrying amount
- AbCellera Biologics Inc.: operating expenses
- AbCellera Biologics Inc.: research and development expense
Inspect the source
- Entity
- AbCellera Biologics Inc. / CIK 0001703057
- Captured
- 2026-09-19T11:20:30.554Z
- SEC response SHA-256
b2742f18d0249f1de2284e7f5a68039ab8f6da582c31075b440162e94660cf3a
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001703057.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))